The results of the CHOICES clinical trial show promise for people with rare CF variants in two exciting ways. The study showed that a new triple combination CFTR modulator therapy, developed by FAIR Therapeutics, was found to be safe and beneficial in many people with CF with rare CF variants. Participants were selected for the trial by testing their responsiveness to the trial medicines in lab tests following a biopsy.
CF diabetes is a difficult illness to manage alongside other CF symptoms, increasing the burden of treatment and risk of long term complications. In this Development Award, Dr Ildem Akerman and Prof Victoria Salem are exploring a new way to treat it.
If you're taking your research through clinical development, we offer expert support and services to accelerate your progress and support your success.
A tribute fund is a place to remember someone you love by sharing memories, photographs, stories and much more. You can set one up on the form below or contact our In-memory Team to find out more.
Our Involvement Group brings the lived experience of people affected by CF to the heart of what we do. From helping to design research studies to reviewing new information resources, our members use their expertise and voice to shape the work of the Trust, researchers and clinicians. We spoke to Debbie, who has two daughters with CF, about what being part of the group means to her.
